COVID-19 pandemic: a catalyst for accelerating global action on patient safety
The disruption of health systems during the pandemic led to an increase in clinical risks and patient harm due to the accentuation of safety gaps, interruption of essential health services, and failure to provide timely diagnosis and treatment.
Co-evolution of immunity and seasonal influenza viruses
Seasonal influenza viruses cause recurring global epidemics by continually evolving to escape host immunity. The viral constraints and host immune responses that limit and drive the evolution of these viruses are increasingly well understood.
The SARS-CoV-2 Spike Protein Mutation Explorer: using an interactive application to improve the public understanding of SARS-CoV-2 variants of concern
The rapid evolution of SARS-CoV-2 resulted in variations in the spike that enhanced transmissibility or weakened vaccine protection.
TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry
SARS-CoV-2 is associated with broad tissue tropism, a characteristic often determined by the availability of entry receptors on host cells.
Dispersal patterns and influence of air travel during the global expansion of SARS-CoV-2 variants of concern
Long Covid: clues about causes
This investigated the monocyte and inflammatory profiles of individuals who were hospitalised with COVID-19 during the acute phase and the convalescent period.
SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination
This study demonstrates durable yet compartmentalised nasal IgA and plasma antibody responses to SARSCoV-2 after infection and subsequent vaccination.
Cotransfer of antigen and contextual information harmonizes peripheral and lymph node conventional dendritic cell activation
T cell responses against infections and cancer are directed by conventional dendritic cells (cDCs) in lymph nodes distant from the site of challenge.
Long-Term Dysfunction of Taste Papillae in SARS-CoV-2
Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials
Nirsevimab is a monoclonal antibody that binds to the RSV fusion protein. During the Phase 2b (NCT02878330) and MELODY (NCT03979313) clinical trials, infants received one dose of nirsevimab or placebo before their first RSV season.
BTN3A3 evasion promotes the zoonotic potential of influenza A viruses
Spillover events of avian influenza A viruses (IAVs) to humans could represent the first step in a future pandemic. Several factors that limit the transmission and replication of avian IAVs in mammals have been identified.
The Path Towards Effective Respiratory Syncytial Virus Immunization Policies: Recommended Actions
RSV causes a substantial burden worldwide. After over six decades of research, there is finally a licensed immunization option that can protect the broad infant population, and other will follow soon.